Autoantibody production is commonly associated with particular HLA class II phenotypes. The aim of the present study was to investigate whether the presence of antiphospholipid (APL) antibodies and other autoantibodies in women with unexplained recurrent miscarriage was associated with particular human leukocyte antigen (HLA)-DR or -DQ alleles or linked epitopes which have previously been reported as being associated with the recurrent miscarriage syndrome or the presence of APL. In a total of 123 Danish and Czech women with recurrent miscarriage, serum was investigated for six different APL antibodies including anticardiolipin (ACL) antibody. Antinuclear antibodies (ANA), anti-zona pellucida antibodies and anti-sperm antibodies were also investigated. The women were HLA-DR and -DQ typed by DNA-based methods. The frequency of HLA-DR phenotypes did not differ significantly between APL antibody positive recurrent miscarriage patients and APL antibody negative recurrent miscarriage patients or healthy controls. Among ACL antibody positive recurrent miscarriage patients, significantly more were positive for the HLA-DR3 phenotype and negative for the HLA-DR2 phenotypes compared with healthy controls (P < 0.05). Among ANA positive recurrent miscarriage women, 55% carried the HLA-DR3 phenotype compared with 28% of ANA negative patients (P < 0.05) and 21% of healthy controls (P < 0.002). In conclusion, among recurrent miscarriage women, the HLA-DR3 phenotypes seem to predispose to formation of ACL antibodies and ANA. The association between APL antibodies and particular HLA alleles and HLA-linked epitopes reported in studies of patients with lupus erythematosus (e.g. HLA-DR7 and -DR4) could not be confirmed in patients with recurrent miscarriage.
Introduction
Antiphospholipid (APL) antibodies are autoantibodies directed against negatively charged phospholipid molecules which 3326 © European Society of Human Reproduction and Embryology constitute the inner layer of biological membranes. The most common epitopes against which APL antibodies are directed are cardiolipin, phosphatidic acid, phosphatidylethanolamine, phosphatidyl-DL-glycerol, phosphatidyl-inositol and phosphatidyl-L-serine. The antibodies can be measured in serum by enzyme immmunosorbent assays (ELISA). Some APL (lupus anticoagulant: LA) are directed against the prothrombinasephospholipid complex of the coagulation cascade and prolong various phospholipid-dependent coagulation tests (e.g. activated partial thromboplastin time: APTT) and are associated in vivo with venous and arterial thrombosis. Both LA measured by coagulation tests and APL antibodies measured by ELISA are statistically associated with unexplained recurrent miscarriage (Cowshock et al., 1986; Unander et al., 1987; Christiansen et al., 1992 Christiansen et al., , 1996 . Several theories have been proposed to explain how these antibodies might impair placental function (Carreras and Vermylen, 1982; Lyden et al., 1992; Rand et al., 1994; Bulletti et al., 1996) ; however, no definitive proof exists that the antibodies cause fetal death.
In patients with systemic lupus erythematosus (SLE) and in other patients without recurrent miscarriage, the presence of APL antibodies seems to be associated with particular human leukocyte antigen (HLA) class II alleles (Savi et al., 1988; McHugh et al., 1989) . The present study on a possible association between HLA class II alleles and the presence of a series of APL antibodies in Danish and Czech women with recurrent miscarriage was undertaken to explore whether the genetic background for APL antibodies in recurrent miscarriage patients is similar to that of non-recurrent miscarriage patients. Another purpose was to investigate whether previously reported associations between class II HLA alleles and recurrent miscarriage could be secondary to an association between APL antibody formation and these alleles.
Materials and methods

Effect parameters
The primary effect parameter was the phenotypic frequency of 11 serologically defined HLA-DR specificities in women with recurrent miscarriage who proved positive for at least one of the tested APL antibodies compared with the corresponding frequencies in women with no APL antibodies and in previously HLA-DR typed Danish controls.
Secondary effect parameters were (i) the frequency of APL antibody positive recurrent miscarriage patients with the HLA-DR1 and/or -DR3 allele compared with APL negative patients and, (ii) the frequencies of HLA-DR specificities in patients with sperm antibodies, zona pellucida antibodies or antinuclear antibodies.
Patients
According to the protocol it was planned to enrol a total of at least 120 women of Danish and Czech Caucasian ethnic origin with a history of recurrent miscarriage. A total of 123 women was actually enrolled. Blood samples were collected from 36 Czech recurrent miscarriage patients who had been admitted to the Clinic of Reproductive Immunology in Pilsen, Czech Republic. The Danish blood samples had previously been obtained from 87 Danish recurrent miscarriage patients, who were admitted to the Department of Obstetrics and Gynaecology, Aalborg Hospital, Denmark during the period 1986 to 1996.
All patients with recurrent miscarriage who were included had had at least three consecutive, confirmed miscarriages. None of the patients had uterine anatomical abnormalities as evaluated by hysterosalpingography or hysteroscopy. All couples had normal chromosomomes and all women had regular menses with intervals of 25-35 days.
Controls
Cut-off levels for positivity for each of the tested APL antibodies were established after investigation of relevant control groups from the Czech Republic.
Controls for the APL antibodies [except anticardiolipin (ACL) antibodies] comprised 258 Czech women aged 22-41 years (mean 24 years). Controls for the ACL antibodies were 148 healthy Czech women with children and without fertility problems aged 21-38 years (mean 26 years).
Since the results of the control groups were clearly not normally distributed, cut-off levels based on standard deviations were not used. The cut-off values for APL antibodies except ACL antibodies were established as the 95% centile whereas the cut-off values for ACL antibodies have previously been established as 2 multiples of the median. The cut-off values for APL antibodies of IgG and IgM class, respectively, were: antiphosphatidic acid 0.242 and 0.297 µg/l; antiphosphatidylethanolamine 0.184 and 0.207 µg/l; antiphosphatidylglycerol 0.209 and 0.258 µg/l; antiphosphatidylinositol 0.206 and 0.254 µg/l; antiphosphatidylserine 0.512 and 0.492 µg/l and ACL 1.0 and 1.0 µg/l. Controls for the prevalence of HLA-DR phenotypes comprised 360 randomly selected healthy Danish individuals. They had been HLA-DR typed in a previously published case-control study of the prevalence of HLA class II alleles in Danish recurrent miscarriage women and controls (Christiansen et al., 1994) .
Determination of antiphospholipid antibodies
APL antibodies of IgG and IgM class were determined by ELISA methods at the Charles University, Pilsen. Briefly, polystyrene microtitre plates were coated with 50 µl of phospholipid (50 µg/ml) in methanol) and the plates were allowed to dry overnight at 4°C. The plates were then blocked for 30 min with 100 µl of Tris-buffered saline (TBS) containing 10% fetal calf serum at room temperature. After washing, serum from patients and a negative control diluted 1:50 in TBS containing 10% fetal calf serum was added to the wells. The plates were incubated for 2 h at room temperature, then washed five times with TBS containing 0.05% Tween 20. A total of 50 µl of peroxidase-conjugated antihuman immunoglobulin (IgM and IgG) was added and incubated for 1 h at room temperature. After incubation, the plates were washed five times in TBS-Tween 20, 50 µl of substrate solution were added to each well and incubated at room temparature in the dark for 30 min. The reaction was stopped by addition of 50 µl of 2 M sulphuric acid.
The optical density of each well was determined with the plate reader Titertek Multiskan MNN/340 (Titertek Instruments Inc., Huntsville, AL, USA) at 492 nm. Background optical density was 3327 run in all patient sera diluted 1:50 in the wells after the same microtitre plates were coated with methanol but no phospholipids. The phospholipids used to coat the ELISA plates were: L-alphaphosphatidic acid, L-alpha-phosphatidylethanolamine, L-alpha-phosphatidyl-DL-glycerol, L-alpha-phosphatidyl-inositol and L-alpha-phosphatidyl-L-serine. ACL antibodies of IgG and IgM class were determined by an ELISA method developed by SEVAC, Prague, Czech Republic. All ELISA assays were performed in duplicate.
Determination of non-antiphospholipid autoantibodies
Sperm antibodies were analysed in Pilsen by the Friberg microagglutination test and by the mixed antiglobulin reaction (MAR) test (Ulcova-Gallova, 1994) . Zona pellucida antibodies were analysed in Pilsen by the passive haemagglutination test and ELISA test (UlcovaGallova and Mardesic, 1996) . The cut-off values are given in the references.
Antinuclear antibodies (ANA) were investigated in Aalborg by fluorescence on mouse fibroblasts and Hep2 cells. A titre of ജ20 was considered positive.
HLA-DR and -DQ typing
HLA-DR and -DQ typing was done using the polymerase chain reaction-sequence-specific primers (PCR-SSP) method by Olerup and Zetterquist (1992) . Briefly, DNA was isolated from nucleated blood cells. Sequence-specific amplification of the DRB1 alleles was carried out using 5Ј and 3Ј primers identifying polymorphisms corresponding to the serologically defined alleles DR1-DRw18 and the DR51, DR52 and DR53 super-specificities in 24 different PCR reactions (Dynal A.S., Oslo, Norway). With regard to identification of HLA-DQ alleles, 5Ј and 3Ј primers identifying DQA1*0101 to DQA1*0601 and DQB1*0501-0505, DQB1*0611-0612, DQB1*0201-0203, DQB1*0301-0306 and DQB1*0401-0402 alleles were used in the PCR reactions. For each individual, the PCR reactions were carried out using a DNA Thermal Cycler (PerkinElmer Gene Amp 9600). In the statistical analysis, PCR-SSP-detected alleles were translated to the previously defined serological HLA-DR specificities.
Statistics
A pilot study had previously shown that at least 50% of the Danish and Czech patients proved positive for one or more APL. The results of the pilot study also suggested that HLA-DR3 might be increased in APL positive recurrent miscarriage patients. A subsequent sample size calculation showed that inclusion of 120 recurrent miscarriage patients would provide the study with a power of 90% to detect a statistically significant (α ϭ 0.05; β ϭ 0.10) increase of the frequency of the HLA-DR3 phenotype among APL positive recurrent miscarriage patients if the real HLA-DR3 frequency in these patients were 30% higher than in controls (who have a HLA-DR3 prevalence of 21%, Table II) .
Comparisons of the HLA phenotypic frequencies between patient subsets and controls were undertaken by the χ 2 -test or Fisher's exact test (when numbers were small). Corrections for the number of comparisons performed were undertaken by multiplying the Pvalues by the number of alleles tested which resulted in the P c -value. P Ͻ 0.05 was considered statistically significant.
Results
The Danish recurrent miscarriage patients comprised 35, 29, 11 and 12 with 3, 4, 5 and ജ6 previous miscarriages, respectively. The Czech recurrent miscarriage patients comprised 27, 2, 2 and 5 with 3, 4, 5 and ജ6 miscarriages, Figure 1 . The frequency of positivity for at least one of the investigated antiphospholipid antibodies (APL) and positivity for anticardiolipin antibodies (ACL) in particular in patients with recurrent miscarriages according to the number of previous pregnancy losses. Controls (no miscarriage) were used to establish cut-off values but these data are not shown because APL were investigated in one control group (n ϭ 258) whereas ACL were investigated in a totally different control group (n ϭ 148) by the manufacturer of the ACL assay (Serac, Prague, Hungary). Figures above each column indicate the absolute number of patients in the subset positive for the antibody in question. respectively. The two distributions were significantly different (P Ͻ 0.005) with the Danish patients having had more previous miscarriages. Figure 1 shows the frequency of APL or ACL antibody positive patients according to the number of previous miscarriages. The frequency of APL antibody positive patients remained constant with increased number of miscarriages. There was a tendency for an increased frequency of ACL positivity in patients with ജ6 miscarriages compared with those with fewer miscarriages (47 versus 33%), however this was not significant. Table I shows the HLA-DR phenotypes of the Danish and Czech recurrent miscarriage patients. Several of the HLA-DR phenotypes were found with very different frequencies in the two populations (e.g. DR1, DR3, DR4, DR5, DR13 and DR7) and the frequencies of DR4 and DR7 were significantly different (P Ͻ 0.05). Table II shows the HLA-DR phenotypes of Danish and Czech recurrent miscarriage patients according to being posit-3328 ive or negative for at least one APL antibody. There were no significant differences between the HLA-DR phenotype distribution of APL antibody positive patients and APL negative patients or Danish controls. When looking at recurrent miscarriage patients who were positive for at least three APL we found that HLA-DR1 and -DR3 positive patients were (non-significantly) increased and HLA-DR2 positive patients almost significantly decreased (non-significantly) as compared with controls. Table III shows that significantly fewer ACL antibody positive patients of both nationalities were HLA-DR2 positive and significantly more ACL positive patients were HLA-DR3 positive compared with the control group (P Ͻ 0.05). Among ACL antibody positive patients, the frequency of the HLA-DR1 and/or -DR3 phenotype also was significantly increased compared with controls (P Ͻ 0.05).
Among patients who were APL antibody positive, 31% were positive for the HLA-DQ7 specificity whereas among APL antibody negative patients, 33% were HLA-DQ7 positive (not significantly different). Among ACL antibody positive and negative patients, 30 and 33%, respectively, were HLA-DQ7 positive (not significantly different).
Among both APL antibody positive and negative patients, 84% were positive for the TRAELDT epitope expressed by the HLA-DQB1*03 and *06 alleles. Among ACL antibody positive and negative patients, 79 and 89% respectively were positive for the TRAELDT epitope (not significantly different). Table IV shows the distribution of HLA-DR phenotypes in recurrent miscarriage patients being positive or negative for ANA. The frequency of the HLA-DR3 phenotype was significantly higher among ANA positive patients than among ANA negative patients (P Ͻ 0.05) and among controls (P Ͻ 0.002, P c Ͻ 0.02).
Nineteen patients were positive for zona pellucida antibodies. Seven of these (37%) were HLA-DR3 positive compared with 29% of patients who were negative for the antibodies (not significantly different). Only six patients were positive for sperm antibodies. Of these, two were carrying the HLA-DR3 allele but the numbers were too small for meaningful statistical comparisons.
Discussion
Autoantibody formation in autoimmune diseases such as SLE is partly under the control of HLA class II alleles. HLA-DR3 is associated with anti-Ro (Alvarellos et al., 1983; Smolen et al., 1987) and HLA-DR2 with anti-DNA antibodies (Alvarellos et al., 1983) and anti-ribosomal P protein antibodies (Arnett et al. 1996) . HLA-DR4 has been reported to be associated with anti-RNP and anti-Sm antibodies (Smolen et al., 1987) .
APL antibodies are found in~20% of SLE patients (McHugh et al., 1989; Goldstein et al., 1996) and the antibodies are also found with increased prevalence in patients with recurrent miscarriage (Cowchock et al., 1986; Unander et al., 1987; Christiansen et al., 1992) .
The reason that some individuals form APL antibodies is unknown but the relationship between HLA class II alleles 
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and other autoantibodies makes it probable that class II alleles also predispose to APL antibody formation. Previous studies in SLE patients have reported that ACL antibodies are associated with HLA-DR7 (Savi et al., 1988) or HLA-DR4 (McHugh et al., 1989) . Camps et al. (1995) reported significant associations between HLA-DQ7, -DR4 and -DRw53 and the primary APL antibody syndrome. Goldstein et al. (1996) reported that the presence of ACL and/or LA was associated with HLA-DR7, HLA-DRw53 and HLA-DQ7 in patients with SLE or the primary APL antibody syndrome. On the other hand, Colucci et al. (1992) found that individuals with the HLA-B8,DR3 haplotype displayed significantly higher levels of APL antibodies than those without this haplotype. Wilson et al. (1995) found that the presence of ACL antibodies in families was associated with the coexistence of alleles for complement factor C4 deficiency (HLA-linked). DQB1 alleles containing the TRAELDT amino acid sequence in their outer domain (DQB1*03 and *06 alleles) have been reported to be associated with LA in patients with connective tissue diseases (Arnett et al., 1991; Wilson et al., 1995) .
Although the results are not in complete agreement, the bulk of the evidence points at HLA-DR4, -DR7 and -DQ7 as primary candidates for being HLA risk factors for the development of ACL antibody.
Until now, only one study has reported that ACL antibodies in women with recurrent miscarriage are also associated with the HLA-DR7 since 40% of ACL antibody positive Italian recurrent miscarriage patients compared with 8% of ACL negative patients had the DR7 phenotype (Trabace et al., 1991) .
In a group of patients with and without ACL antibodies, Christiansen et al. (1994) reported that recurrent miscarriage was associated with the HLA-DR1 and -DR3 alleles. A prospective study and a family study (Christiansen et al. 1993 (Christiansen et al. , 1995 confirmed that these alleles predisposed to miscarriage in recurrent miscarriage patients and their family members. A subsequent meta-analysis of published studies showed that HLA-DR1, -DR3 and -DR4 was associated with recurrent miscarriage (Christiansen et al., 1997) .
The main aim of the present study was to investigate whether the presence of APL was associated with particular HLA class II alleles. In this respect, the HLA alleles DR7, -DR4, -DQ7, -DR3 and -DR1 were of particular interest due to the aforementioned previously published associations.
The study is the largest so far published on the association between APL antibodies and HLA in patients with recurrent miscarriage. Completion of the study required the collaboration between two laboratories: the Czech laboratory which possesed the techniques and resources for investigating a wide range of APL antibodies and the Danish laboratory which had the techniques and resources for making the DNA-based HLA typings. Collaboration was also required to collect serum and DNA samples from at least 120 patients with unexplained recurrent miscarriage -the number needed for the study according to the protocol.
The study population thus comprised both Danish and Czech recurrent miscarriage patients. We believe it is possible to combine the data from the two different populations and compare Czech recurrent miscarriage patients with Danish controls since the Czech and Slovak populations seem to display HLA class II allele frequencies similar to other Central European Caucasian populations (Loudova et al., 1996; Cechova et al., 1998) and Czechs seem to display the same statistical associations between autoimmune disease and HLA class II genes as found in other Caucasian populations (Martinelli et al., 1995) . However, the Danish and Czech recurrent miscarriage patients included in the present study seem to be basically different with regard to HLA-DR distribution, since two alleles (HLA-DR4 and -DR7) displayed significantly different frequencies between the two groups (Table  I) . This difference can probably be explained partly by the fact that the Danish recurrent miscarriage patients had had significantly more previous miscarriages than the Czech patients, since the prevalence of the HLA-DR1 and -DR3 alleles has been reported to increase with increased number of miscarriages (Christiansen et al., 1995) .
In the combined group of ACL antibody positive Danish and Czech patients, HLA-DR2 was found with a significantly decreased, and HLA-DR3 with a significantly increased, 3330 frequency compared with normal controls (Table III) . However, if correction for multiple comparisons is undertaken the differences will not remain significant.
Since HLA-DQ7 in Caucasian populations is found primarily on haplotypes with the DR5 or the DR4 allele, which are increased neither in APL nor ACL antibody positive patients, it is not surprising to find quite similar phenotypic frequencies of DQ7 in APL/ACL antibody positive and negative patients.
We found no differences in the occurrence of the TRAELDT epitope (DQB1*03 and *06 alleles) between APL/ACL antibody positive and negative recurrent miscarriage patients.
In conclusion, we cannot find evidence that HLA-DR4, -DR7, -DQ7 or the TRAELDT epitope are associated with formation of APL antibodies and in particular ACL antibodies in patients with recurrent miscarriage. ACL antibody formation, on the other hand, might be associated with the same alleles which predispose to recurrent miscarriage (at least in the general Danish recurrent miscarriage population): HLA-DR1 and -DR3. The ACL antibodies found in recurrent miscarriage women might be similar to those described by Colucci et al. (1992) since they are not or only weakly associated with thrombosis and display association to HLA-DR3.
The failure of the present study to confirm previously reported associations between HLA-DR phenotypes and the presence of APL might, in theory, be due to the assignment of recurrent miscarriage patients with only transient positive APL tests to the APL positive group. Since APL tests might be transiently positive after infections, it has been proposed (Rai et al., 1995) that only patients with persistently positive APL tests should be classified as suffering from antiphospholipid syndrome. Our previous experience is that 50% of ACL positive recurrent miscarriage patients are persistently ACL positive in repeated tests (Christiansen et al., 1992) . However, the published reports of associations between the presence of APL and particular HLA alleles have, similar to our study, also based the assignment of patients as being APL positive on a single test. When looking at recurrent miscarriage patients who are positive for at least three APL tests, we found a pattern of HLA-DR distribution similar to that of all ACL positive patients: HLA-DR1 and -DR3 positive patients being (non-significantly) increased and HLA-DR2 positive patients almost significantly decreased as compared with controls. Patients with at least three APL are likely to be persistently positive for at least one APL at repeated testings so this subset might represent those with the real antiphospholipid syndrome. It is interesting that these patients (and those with ACL antibodies) exhibit the same pattern of HLA-DR distribution as previously reported among all Danish recurrent miscarriage patients with at least four miscarriages regardless of their APL status.
Whether APL or ACL antibodies cause miscarriage in recurrent miscarriage patients is still unclear. The data in Figure 1 showing no correlation between the severity of the disease (the number of previous miscarriages) and the prevalence of APL or ACL antibodies argue against a causative role for these antibodies in recurrent miscarriage, at least with the cut-off values used in the present study.
Formation of autoantibodies in recurrent miscarriage patients might be an epiphenomenon secondary to a T helper type 1 cytokine response against trophoblast which might play a role in the pathogenesis of recurrent miscarriage (Christiansen, 1996; Lim et al., 1996) We found that the presence of ANA was highly associated with the HLA-DR3 allele (Table IV) and the P-value remained Ͻ0.05 even after corrections for multiple comparisons.
Our findings have implications for studies of HLA allele frequencies in women with recurrent miscarriage. In a substantial proportion of these studies, patients with ACL antibodies, ANA and other autoantibodies are excluded. Such an exclusion is expected to deplete the patient group for HLA-DR3 positive individuals which will result in a skewed picture of the real HLA distribution in the population of recurrent miscarriage patients.
